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Background
On the basis of effectiveness of bisphosphonates in
adults, a simple protocol for the treatment of low bone
mineral density in children was developed in 1995 in our
centre. Objectives: To review the effectiveness of a single-
day infusion of pamidronate twice a year in children. Sec-
ondary, to describe its efficacy in relation to the etiology
of osteoporosis.
Materials and methods
Retrospective review of patients treated with pamidronate
from January 1995 to June 2006 in Sant Joan de Déu hos-
pital (Spain). Patients:younger than 18 years that under-
went treatment with the protocol for at least one year and
with z-score < -2.5, fractures and z-score < -1 or docu-
mented bone pain with z-score < -1. They were classified
into 4 groups: osteogenesis imperfecta, chronic treatment
with steroids, disuse and other conditions. Interventions:
single intravenous administration of pamidronate (30 mg
in prepubescent patients and 60 mg in all other patients)
every six months. Clinical, radiological data and bone
mineral density were obtained basal and after each cycle.
For each patient the ratio fractures/year during the treat-
ment and the total increase in z-score (total ΔZ) after the
treatment were calculated.
Results
56 patients were included. Overall, fractures/year
decreased from 1.75 basal to 0.46 during the treatment.
Osteogenesis imperfecta group had better total ΔZ (1.25).
Disuse group had clinical improvement although poor
total ΔZ increase (0.12).
Conclusion
There is a clinical improvement in all patients. The OI
group has the best gain in bone mineral mass. The proto-
col is safe, simple and well tolerated by patients and fam-
ilies.
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